ArticleAmerican health & drug benefits2016
Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma.
Article in American health & drug benefits, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Infection risks associated with daratumumab-containing regimens in multiple myeloma: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Advances in Oncohematology Immunotherapy: Monoclonal Antibodies and CAR T-Cell Therapies.Cells · 2026Review
- Article
- Aseptic meningitis induced by monoclonal antibodies used in cancer treatment: a systematic review.Research in pharmaceutical sciences · 2026Review
- Fulminant extramedullary relapse of multiple myeloma with rare cardiac, vascular, and multivisceral involvement: A case report.Therapeutic advances in hematology · 2026Article
- Daratumumab-induced acute angle closure glaucoma: bone marrow transplantation as a possible risk factor and atropinization as a potential solution.BMC ophthalmology · 2025Article
- Leptomeningeal Involvement in Relapsed Multiple Myeloma With Thoracic Spine and Orbital Metastases: A Case Report.Cureus · 2025Article
- Immunosenescence in Sepsis: Molecular Mechanisms and Potential Therapeutic Targets.Aging and disease · 2025Review
- Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment.Bioactive materials · 2024Review
- Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial.Nature communications · 2024Article
- Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 to 2022.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands.International journal of molecular sciences · 2024Article
- Recurrence of solitary plasmacytoma in the liver 10 years after the onset of multiple bone lesions.Journal of clinical and experimental hematopathology : JCEH · 2024Article
- NADase CD38 is a key determinant of ovarian aging.Nature aging · 2024Article
- Effect of anti-CD38 monoclonal antibodies on hepatitis C virus replication in chronically infected patients with multiple myeloma: a prospective series.Leukemia & lymphoma · 2023Article
- Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction.Translational oncology · 2022Article
- Review
- Nanomedicines in B cell-targeting therapies.Acta biomaterialia · 2022Review
- Acute bilateral angle closure induced by monoclonal antibody (Daratumumab) infusion.American journal of ophthalmology case reports · 2021Article
- Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.Journal for immunotherapy of cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
27668047PMC5013856What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.